Truist Securities Reiterates Buy Rating on Kymera Therapeutics (KYMR) Following Sector Deal

June 22, 2026 11:24 AM

Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $116.00 price target on Kymera Therapeutics (NASDAQ: KYMR) after AbbVie ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found